Opioid-induced constipation: advances and clinical guidance

Therapeutic Advances in Chronic Disease

Volumn 7, Issue 2, 2016, Pages 121-134

  Nelson, Alfred D ^a   Camilleri, Michael ^a  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

Author keywords

lubiprostone; methylnaltrexone; naloxegol; noncancer pain; peripheral opioid receptor antagonist; tolerance

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; AXELOPRAN; LINACLOTIDE; LUBIPROSTONE; MU OPIATE RECEPTOR; NALDEMEDINE; NALOXEGOL; OLICERIDINE; OPIATE; PRUCALOPRIDE;

ANALGESIA; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CONSTIPATION; DRUG INDUCED DISEASE; HUMAN; OPIOID INDUCED CONSTIPATION; PAIN ASSESSMENT; PATIENT GUIDANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

EID: 84959360356     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622315627801     Document Type: Review

References (91)

1. H.AkbaraliA.InkisarW.Dewey (2014) Site and mechanism of morphine tolerance in the gastrointestinal tract. Neurogastroent Motil26: 1361–1367.
2. H.AminA.SopchakJ.FossB.EspositoM.RoizenE.Camporesi (1994) Efficacy of methylnaltrexone versus naloxone for reversal of morphine-induced depression of hypoxic ventilatory response. Anesth Analg78: 701–705.
3. C.ArgoffM.BrennanM.CamilleriA.DaviesJ.FudinK.Galluzzi. (2015) Consensus recommendations on initiating prescription therapies for opioid-induced constipation. Pain Med. DOI: 10.1111/pme.12937.
4. S.ArmstrongC.CampbellC.RichardsonR.VickeryP.TsurudaD.Long. (2013) The in vivo pharmacodynamics of the novel opioid receptor antagonist, TD-1211, in models of opioid-induced gastrointestinal and CNS activity. Naunyn Schmiedebergs Arch Pharmacol386: 471–478.
5. D.BagnolA.MansourH.AkilS.Watson (1997) Cellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract. Neuroscience81: 579–591.
6. T.BellS.PanchalC.MiaskowskiS.BolgeT.MilanovaR.Williamson (2009) The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (probe 1). Pain Med10: 35–42.
7. R.BenyaminA.TrescotS.DattaR.BuenaventuraR.AdlakaN.Sehgal. (2008) Opioid complications and side effects. Pain Physician11: S105–S120.
8. M.BijveldsA.BotJ.EscherH.De Jonge (2009) Activation of intestinal Cl− secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator. Gastroenterology137: 976–985.
9. L.BohnR.LefkowitzR.GainetdinovK.PeppelM.CaronF.Lin (1999) Enhanced morphine analgesia in mice lacking Β-arrestin 2. Science286: 2495–2498.
10. D.BrownL.Goldberg (1985) The use of quaternary narcotic antagonists in opiate research. Neuropharmacology24: 181–191.
11. A.BryantR.BusbyW.BartoliniE.CorderoG.HannigM.Kessler. (2010) Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci86: 760–765.
12. K.BuiF.SheM.Sostek (2014) The effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegol. J Clin Pharmacol54: 1375–1382.
13. C.BurnessG.Keating (2014) Oxycodone/naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation. Drugs74: 353–375.
14. M.CamilleriA.BharuchaR.UenoD.BurtonG.ThomfordeK.Baxter. (2006) Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol290: G942–G947.
15. M.CamilleriD.DrossmanG.BeckerL.WebsterA.DaviesG.Mawe (2014) Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. Neurogastroent Motil26: 1386–1395.
16. M.CamilleriJ.MalageladaV.StanghelliniA.ZinsmeisterP.KaoC.Li (1986) Dose-related effects of synthetic human beta-endorphin and naloxone on fed gastrointestinal motility. Am J Physiol251: G147–G154.
17. M.CamilleriM.RothmanK.HoM.Etropolski (2011) Validation of a bowel function diary for assessing opioid-induced constipation. Am J Gastroenterol106: 497–506.
18. M.CatalánC.FloresM.González-BegneY.ZhangF.SepúlvedaJ.Melvin (2012) Severe defects in absorptive ion transport in distal colons of mice that lack CLC-2 channels. Gastroenterology142: 346–354.
19. X.ChenP.PitisG.LiuC.YuanD.GotchevC.Cowan. (2013) Structure–activity relationships and discovery of a G protein biased mu opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9r)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan- 9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain. J Med Chem56: 8019–8031.
20. W.CheyL.WebsterM.SostekJ.LappalainenP.BarkerJ.Tack (2014) Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med370: 2387–2396.
21. Y.ChoiJ.Billings (2002) Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation. J Pain Symptom Manage24: 71–90.
22. R.ChouG.FanciulloP.FineJ.AdlerJ.BallantyneP.Davies. (2009) Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain10: 113–130.
23. A.ClaingS.LaporteM.CaronR.Lefkowitz (2002) Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Prog Neurobiol66: 61–79.
24. K.CoyneB.CurrieW.HolmesJ.Crawley (2015) Assessment of a stool symptom screener and understanding the opioid-induced constipation symptom experience. Patient8: 317–327.
25. K.CoyneR.LocasaleC.DattoC.SextonK.YeomansJ.Tack (2014) Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review. Clinicoecon Outcomes Res6: 269–281.
26. B.CryerS.KatzR.VallejoA.PopescuR.Ueno (2014) A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain. Pain Med15: 1825–1834.
27. J.CuppolettiJ.ChakrabartiK.TewariD.Malinowska (2013) Methadone but not morphine inhibits lubiprostone-stimulated Cl- currents in T84 intestinal cells and recombinant human ClC-2, but not CFTR Cl– currents. Cell Biochem Biophys66: 53–63.
28. J.CuppolettiJ.ChakrabartiK.TewariD.Malinowska (2014) Differentiation between human ClC-2 and CFTR Cl– channels with pharmacological agents. Am J Physiol Cell Physiol307: C479–C492.
29. J.CuppolettiD.MalinowskaK.TewariQ.LiA.SherryM.Patchen. (2004) SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol287: C1173–C1183.
30. J.De MaeyerR.LefebvreJ.Schuurkes (2008) 5-HT4 receptor agonists: similar but not the same. Neurogastroent Motil20: 99–112.
31. A.EmmanuelM.KammA.RoyK.Antonelli (1998) Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut42: 511–516.
32. F.FaassenG.VogelH.SpaningsH.Vromans (2003) Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm263: 113–122.
33. P.FineG.MahajanM.McPherson (2009) Long-acting opioids and short-acting opioids: appropriate use in chronic pain management. Pain Med10: S79–S88.
34. J.GaertnerW.SiemensM.CamilleriA.DaviesD.DrossmanL.Webster. (2015) Definitions and outcome measures of clinical trials regarding opioid-induced constipation: a systematic review. J Clin Gastroenterol49: 9–16.
35. J.GalliganH.Akbarali (2014) Molecular physiology of enteric opioid receptors. Am J Gastroenterol2: 17–21.
36. C.GottfridssonG.CarlsonJ.LappalainenM.Sostek (2013) Evaluation of the effect of naloxegol on cardiac repolarization: a randomized, placebo- and positive-controlled crossover thorough QT/QTC study in healthy volunteers. Clinical Therapeutics35: 1876–1883.
37. J.HardmanE.Sutherland (1969)Guanyl cyclase, an enzyme catalyzing theformation of guanosine 3’,5’-monophosphatefrom guanosine triphosphate. J Biol Chem244: 6363–6370.
38. P.Holzer (2004) Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett361: 192–195.
39. W.HootenT.LamerC.Twyner (2015) Opioid-induced hyperalgesia in community-dwelling adults with chronic pain. Pain156: 1145–1152.
40. G.IrvingJ.PénzesB.RamjattanM.CousinsR.RauckE.Spierings. (2011) A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain12: 175–184.
41. S.IyerB.RandazzoE.TzanisS.SchulmanH.ZhangW.Wang. (2011) Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms. Value Health14: 177–183.
42. A.JadadG.Browman (1995) The who analgesic ladder for cancer pain management: stepping up the quality of its evaluation. JAMA274: 1870–1873.
43. R.JakabA.CollacoN.Ameen (2012) Lubiprostone targets prostanoid signaling and promotes ion transporter trafficking, mucus exocytosis, and contractility. Dig Dis Sci57: 2826–2845.
44. M.JamalA.AdamsJ.JansenL.Webster (2015) A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain. Am J Gastroenterol110: 725–732.
45. E.KalsoJ.EdwardsR.MooreH.McQuay (2004) Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain112: 372–380.
46. G.KoopmansK.SimpsonJ.De AndresE.LuxM.WagemansY.Van Megen (2014) Fixed ratio (2:1) prolonged-release oxycodone/naloxone combination improves bowel function in patients with moderate-to-severe pain and opioid-induced constipation refractory to at least two classes of laxatives. Curr Med Res Opin30: 2389–2396.
47. L.KumarC.BarkerA.Emmanuel (2014) Opioid-induced constipation: pathophysiology, clinical consequences, and management. Gastroenterol Res Pract2014: 141737.
48. A.KurzD.Sessler (2003) Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs63: 649–671.
49. G.LingD.PaulR.SimantovG.Pasternak (1989) Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model. Life Sci45: 1627–1636.
50. M.LiuE.Wittbrodt (2002) Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage23: 48–53.
51. O.LowensteinP.LeyendeckerM.HoppU.SchutterP.RogersR.Uhl. (2009) Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother10: 531–543.
52. A.MackeyL.GreenP.GreeneM.Avigan (2010) Methylnaltrexone and gastrointestinal perforation. J Pain Symptom Manage40: e1–e3.
53. K.MansfieldJ.SimJ.JordanK.Jordan (2015) A systematic review and meta-analysis of the prevalence of chronic widespread pain in the general population. Pain157: 55–64.
54. V.MehtaS.AlawardS.KuravinakopS.Nikolic (2014) Effect of a fixed-dose opioid agonist/antagonist on constipation in patients on long-term opioids for non-malignant pain unable to tolerate laxatives. Pain Physician17: 415–424.
55. W.MeissnerP.LeyendeckerS.Mueller-LissnerJ.NadstawekM.HoppC.Ruckes. (2009) A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain13: 56–64.
56. W.MeissnerU.SchmidtM.HartmannR.KathK.Reinhart (2000) Oral naloxone reverses opioid-associated constipation. Pain84: 105–109.
57. E.MichnaE.BlonskyS.SchulmanE.TzanisA.ManleyH.Zhang. (2011a) Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain12: 554–562.
58. E.MichnaA.WeilM.DuerdenS.SchulmanW.WangE.Tzanis. (2011b) Efficacy of subcutaneous methylnaltrexone in the treatment of opioid-induced constipation: a responder post hoc analysis. Pain Med12: 1223–1230.
59. F.MusialP.EnckK.KalveramJ.Erckenbrecht (1992) The effect of loperamide on anorectal function in normal healthy men. J Clin Gastroenterol15: 321–324.
60. A.NelsonM.Camilleri (2015) Chronic opioid-induced constipation in patients with nonmalignant pain: Challenges and opportunities. Ther Adv Gastroenterol8: 206–220.
61. T.NeumannH.Van PatischenA.MarcantonioD.SongP.MorrisonM.Eldon (2007) Evaluation of single oral doses of NKTR118 (PEG-Naloxol) as a peripheral opioid antagonist (POA): a double-blind placebo-controlled study in healthy male subjects. J Clin Pharmacol47: 1210–1210.
62. Y.Pan (2005) Diversity and complexity of the mu opioid receptor gene: alternative pre-mRNA splicing and promoters. DNA Cell Biol24: 736–750.
63. M.Pappagallo (2001) Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg182: S11–S18.
64. G.Pasternak (2001) Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol Sci22: 67–70.
65. J.PoelaertG.Koopmans-KleinA.DiohF.LouisM.GorissenD.Logé. (2015) Treatment with prolonged-release oxycodone/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation. Clin Ther37: 784–792.
66. A.RentzR.YuS.Muller-LissnerP.Leyendecker (2009) Validation of the bowel function index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ12: 371–383.
67. J.RussellP.BassL.GoldbergC.SchusterH.Merz (1982) Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur J Pharmacol78: 255–261.
68. T.RustonK.HunterG.CummingsA.Lazarescu (2013) Efficacy and side-effect profiles of lactulose, docusate sodium, and sennosides compared to peg in opioid-induced constipation: a systematic review. Can Oncol Nurs J23: 236–246.
69. A.Sandner-KieslingP.LeyendeckerM.HoppL.TarauJ.LejckoW.Meissner. (2010) Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract64: 763–774.
70. E.SchiffhauerN.VijO.KovbasnjukP.KangD.WalkerS.Lee. (2013) Dual activation of CFTR and CLCN2 by lubiprostone in murine nasal epithelia. Am J Physiol Lung Cell Mol Physiol304: L324–L331.
71. J.ShookJ.PeltonV.HrubyT.Burks (1987) Peptide opioid antagonist separates peripheral and central opioid antitransit effects. J Pharmacol Exp Ther243: 492–500.
72. C.SlootsA.RykxM.CoolsR.KerstensM.De Pauw (2010) Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Digest Dis Sci55: 2912–2921.
73. K.SmithM.HoppG.MundinS.BondP.BaileyJ.Woodward. (2011) Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers. Expert Opin Investig Drugs20: 427–439.
74. D.SoergelR.SubachN.BurnhamM.LarkI.JamesB.Sadler. (2014a) Biased agonism of the µ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Pain155: 1829–1835.
75. D.SoergelR.SubachB.SadlerJ.ConnellA.MarionC.Cowan. (2014b) First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers. J Clin Pharmacol54: 351–357.
76. J.TackM.Corsetti (2014) Naloxegol for the treatment of opioid-induced constipation. Expert Rev Gastroenterol Hepatol8: 855–861.
77. A.TutejaJ.BiskupiakG.StoddardA.Lipman (2010) Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroent Motil22: 424–430, e496.
78. M.UeberallS.Muller-LissnerC.Buschmann-KrammB.Bosse (2011) The bowel function index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients. J Int Med Res39: 41–50.
79. P.VerhaakJ.KerssensJ.DekkerM.SorbiJ.Bensing (1998) Prevalence of chronic benign pain disorder among adults: a review of the literature. Pain77: 231–239.
80. R.VickeryY.LiR.KohlerL.WebsterN.SinglaO.Daniels (2011) TD-1211 demonstrates constipation-relieving effects, including decrease in rescue laxative use, in patients with opioid-induced constipation. Am J Gastroenterol106: S513–S514.
81. R.VickeryY.LiU.SchwertschlagN.SinglaL.WebsterD.Canafax (2013a) TD-1211 demonstrates a durable increase in bowel movement frequency and return toward normal bowel function in a 5-week PH2B opioid-induced constipation (OIC) study. J Pain14: S78.
82. R.VickeryY.LiU.SchwertschlagN.SinglaL.WebsterD.Canafax (2013b) TD-1211 phase 2b study demonstrates increased bowel movement frequency and constipation-related symptom improvement in patients with opioid induced constipation (OIC). Gastroenterology144: S159.
83. D.VondrackovaP.LeyendeckerW.MeissnerM.HoppI.SzombatiK.Hermanns. (2008) Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain9: 1144–1154.
84. M.WalidS.DonahueD.DarmohrayL.HyerJrJ.RobinsonJr (2008) The fifth vital sign - what does it mean?Pain Pract8: 417–422.
85. L.WebsterW.CheyJ.TackJ.LappalainenU.DivaM.Sostek (2014) Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. Aliment Pharmacol Ther40: 771–779.
86. L.WebsterS.DharM.EldonL.MasuokaJ.LappalainenM.Sostek (2013) A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. Pain154: 1542–1550.
87. L.WebsterJ.JansenJ.PeppinB.LaskoG.IrvingB.Morlion. (2008) Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain137: 428–440.
88. J.WilliamsS.IngramG.HendersonC.ChavkinM.Von ZastrowS.Schulz. (2013) Regulation of mu-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev65: 223–254.
89. B.WongA.RaoM.CamilleriN.ManabeS.McKinzieI.Busciglio. (2010) The effects of methylnaltrexone alone and in combination with acutely administered codeine on gastrointestinal and colonic transit in health. Aliment Pharmacol Ther32: 884–893.
90. C.YuanJ.FossM.O’ConnorA.ToledanoM.RoizenJ.Moss (1996) Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin Pharmacol Ther59: 469–475.
91. C.YuanG.WeiJ.FossM.O’ConnorT.KarrisonJ.Osinski (2002) Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. J Pharmacol Exp Ther300: 118–123.